Lexeo Therapeutics LXEO
NASDAQ LXEO
$3.62 +0.24 (+7.10%)
At close: Oct 1, 2026 · 4:00 PM EDT

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)

Updated

Lexeo Therapeutics (LXEO) reported Preferred Stock Liabilities of $370.07 million for Q3 2023, up 100.0% from $185.03 million a year earlier and up 100.0% from the prior quarter.

Analysis

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

At the end of FY2022, Lexeo Therapeutics posted Preferred Stock Liabilities of $185.03 million.

  • Per Business Quant data, the three quarters before Q3 2023 came in at $185.03 million (Q2 2023), $185.03 million (Q1 2023) and $185.03 million (Q4 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Lexeo Therapeutics 265.74 Mn 265.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 370.07 Mn
Jun 30, 2023 185.03 Mn
Mar 31, 2023 185.03 Mn
Dec 31, 2022 185.03 Mn
Sep 30, 2022 185.03 Mn
API Access

Lexeo Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=LXEO&period=max&api_key=YOUR_API_KEY